NEW YORK (GenomeWeb News) – Takeda Pharmaceutical Company has licensed from CellCentric cancer-related epigenetic target technologies for development and commercialization.
Under the agreement, Takeda's Research Group will conduct therapeutic research on molecules that will be further developed by Millenium, the biopharmaceutical firm that Takeda acquired in 2008.
The agreement includes an up-front payment, clinical and pre-clinical milestones, and royalties. Overall, the pact could reap as much as $200 million for CellCentric over the course of the agreement.
The CellCentric technology is based on epigenetic alterations caused by a range of enzymes that can be targeted and may be of use in cancer treatment, including histone methyltranserases, demethylases, and ubiquitin-related enzymes.
CellCentric CEO Will West said in a statement that epigenetics "is an area that is no longer seen as just interesting, but as a necessity for pharmaceutical companies growing their armory for tackling intractable diseases such as cancer."